TNFRSF8 expression

P1, N=22, Terminated, Seagen, a wholly owned subsidiary of Pfizer | Completed --> Terminated; Study terminated as part of strategic considerations

In further studies, RNA sequencing confirmed the presence of NPM1::ALK gene fusion in this case; whole-exome sequencing (WES) detected somatic mutations in multiple genes of the JAK-STAT pathway (including JAK1, PTPN6, MTOR, and TYK2). It is noteworthy that such genetic alterations are more commonly observed in ALK-negative anaplastic large cell lymphoma (ALK-ALCL) but are less commonly reported in ALK+ALCL.

P2, N=30, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2026 --> Jan 2027

P1, N=22, Completed, Seagen, a wholly owned subsidiary of Pfizer | Active, not recruiting --> Completed

While response rates were similar, PFS was shorter. These findings suggest that BV remains a potential therapeutic option in this patient population and merits further prospective investigation.

Subsequently, dual-luciferase reporter assays and chromatin immunoprecipitation (ChIP)-qPCR demonstrated that Meq directly bound to the CD30 promoter to activate its transcription, and the primary binding regions located at -1383 to -1162 bp and -97 to +75 bp relative to the transcription start site. Collectively, this study demonstrated Meq could bind to CD30 promoter at two binding regions and up-regulate its expression, and provided a critical foundation to investigate the role of the CD30 signaling pathway in MD-induced tumorigenesis.

This understanding provides a strong rationale for COO- and TME-guided therapeutic strategies, such as combining the anti-CD30 antibody-drug conjugate brentuximab vedotin with immunomodulatory agents. This report elucidates the enigma of CD30 and outlines a path towards personalized medicine for DLBCL.

RDD of the lung and mediastinum is rare, with a wide range of ages. Histologically, there are often lymphoid follicles with germinal centers and interstitial fibrosis or sclerosis. This together with the expression of BCL2 and CD30 in the histiocytes can lead to misdiagnosis of lymphomas or other lymphoproliferative diseases or missed diagnosis, particularly in the mediastinum. Careful histological examination for the diagnostic feature of emperipolesis together with characteristic Cyclin D1, OCT2, S100 protein, and CD68 positivity are important clues for accurate diagnosis.

AITL with HRS-like cells is prone to misdiagnosis as CHL due to overlapping morphological and immunophenotypic features. Integration of EBER, TCR/IG clonality assessment, and molecular profiling, particularly the identification of TET2 and RHOA mutations is essential for accurate classification. Recognizing this entity is critical for avoiding diagnostic pitfalls and guiding appropriate therapeutic strategies.

He commenced first-line systemic therapy with methotrexate, but had no response. He was switched to brentuximab vedotin and has received eight cycles with partial response...Approach to mycosis fungoides in children: consensus-based recommendations. J Am Acad Dermatol 2024; 91: 1078-85).

P1, N=43, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center | Recruiting --> Active, not recruiting | Trial completion date: Sep 2041 --> Nov 2039 | Trial primary completion date: Sep 2026 --> Dec 2025

P1/2, N=38, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center | Recruiting --> Active, not recruiting | Trial completion date: Aug 2038 --> Nov 2039 | Trial primary completion date: Sep 2027 --> Dec 2025